Advancing Vaccine Formulations of Importance to Developing Countries Using New and Existing Adjuvant Technologies

The positive impact of adjuvants on vaccination can be functional and practical. A handful of adjuvants are currently licensed for human vaccination, and a number of new adjuvants have reached advanced development stages. However, access to these and other adjuvants is limited. Presented at the 2012 Conference on Modern Vaccines Adjuvants and Delivery Systems, this poster outlines PATH’s work to expand access to proprietary and non-proprietary adjuvants as well as relevant formulations technologies to facilitate their successful exploration and use by product development partnerships and developing-country vaccine manufacturers.

Author(s): Blum J, Chen D, Cummings R

Published: 2012

  • Download file (English)

    564 KB PDF

    Citation: Blum J, Chen D, Cummings R. Advancing Vaccine Formulations of Importance to Developing Countries Using New and Existing Adjuvant Technologies. Presented at: 2012 Conference on Modern Vaccines Adjuvants and Delivery Systems, July 2012; Copenhagen, Denmark.